Financing ·
Amylyx Pharmaceuticals entered into an underwriting agreement on August 19, 2026, to sell 14,090,000 shares of common…
AMLXAmylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals entered into an underwriting agreement on August 19, 2026, to sell 14,090,000 shares of common stock at $35.50 per share. The company granted underwriters a 30-day option to purchase up to 2,113,500 additional shares. Net proceeds are expected to be approximately $471.7 million, or $542.5 million if the option is exercised in full. The offering is scheduled to close on August 21, 2026. Amylyx intends to use the net proceeds to fund the potential commercial launch of avexitide in the United States, secure manufacturing capacity, and support research and development activities. This company operates in the biopharmaceutical industry, focusing on drug discovery and development for neurodegenerative diseases.